aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of innovative therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler in 2005 and is headquartered in San Diego, CA.
Market Cap | 79.496 Million | Shares Outstanding | 27.796 Million | Avg 30-day Volume | 87.115 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.42 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -37.334 Million |
Price to Book Value | 1.5231 | Operating Margin | 0.0 | Enterprise Value | 51.259 Million |
Current Ratio | 16.449 | EPS Growth | 0.225 | Quick Ratio | 15.807 |
1 Yr BETA | 0.9428 | 52-week High/Low | 13.1 / 2.6 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -61.1619 | Altman Z-Score | 8.8055 | Free Cash Flow to Firm | -28.247 Million |
Earnings Report | 2022-08-10 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
BROADFOOT JILL MARIE CHIEF FINANCIAL OFFICER |
|
87,637 | 2022-05-24 | 3 |
DENYES NANCY GENERAL COUNSEL |
|
91,544 | 2022-05-24 | 2 |
SHUKLA SANJAY PRESIDENT AND CEO |
|
516,280 | 2022-05-24 | 4 |
|
6,000 | 2022-04-26 | 1 | |
|
6,000 | 2022-04-26 | 2 | |
|
6,000 | 2022-04-26 | 1 | |
|
6,000 | 2022-04-26 | 1 | |
|
6,000 | 2022-04-26 | 1 | |
|
6,000 | 2022-04-26 | 1 | |
|
0 | 2020-05-06 | 0 | |
|
0 | 2019-05-08 | 0 | |
|
0 | 2019-05-08 | 0 | |
AMANULLAH ASHRAF SEE REMARKS |
|
No longer subject to file | 2018-05-31 | 0 |
|
0 | 2018-05-15 | 0 | |
|
No longer subject to file | 2018-05-14 | 0 | |
|
11,954 | 2018-03-20 | 0 | |
BLAKE JOHN T SENIOR VICE PRESIDENT, FINANCE |
|
1,932 | 2018-02-06 | 0 |
KING DAVID JOHN CHIEF SCIENTIFIC OFFICER |
|
0 | 2018-02-06 | 0 |
|
0 | 2017-05-09 | 0 | |
|
0 | 2017-05-09 | 0 | |
RAVINDRAN SANUJ K. CHIEF BUSINESS OFFICER |
|
0 | 2017-02-07 | 0 |
MATSUOKA GROVE SEE REMARKS |
|
0 | 2017-02-07 | 0 |
CUBITT ANDREW VP, PRODUCT PROTECTION |
|
0 | 2016-09-13 | 0 |
|
0 | 2016-05-24 | 0 | |
BLACKBURN KELLY VP, CLINICAL AFFAIRS |
|
0 | 2016-03-28 | 0 |
CHRZANOWSKI HOLLY D. SEE REMARKS |
|
0 | 2016-01-27 | 0 |
MCKEW JOHN C. VP, RESEARCH |
|
0 | 2016-01-27 | 0 |
ASHLOCK MELISSA A. SEE REMARKS |
|
0 | 2016-01-27 | 0 |
GRAHAM MARCY SEE REMARKS |
|
0 | 2016-01-04 | 0 |
RAMSDELL FRED VP, IMMUNOLOGY |
|
0 | 2015-10-01 | 0 |
|
No longer subject to file | 2015-05-12 | 0 | |
|
13,414 | 2015-05-12 | 0 | |
|
1,807,820 | 2015-05-12 | 0 | |
|
No longer subject to file | 2015-05-12 | 0 | |
|
No longer subject to file | 2015-05-12 | 0 | |
SOFINNOVA VENTURE PARTNERS IX, L.P. |
|
No longer subject to file | 2015-05-12 | 0 |
POLARIS VENTURE MANAGEMENT CO. V, L.L.C. POLARIS VENTURE PARTNERS V, L.P. POLARIS VENTURE PARTNERS ENTREPRENEURS' FUND V, L.P. |
|
No longer subject to file | 2015-05-12 | 0 |
|
12,572 | 2015-05-06 | 0 | |
SOFINNOVA VENTURE PARTNERS IX, L.P. |
|
0 | 2015-05-06 | 0 |
CHEREAU FREDERIC COO & PRESIDENT |
|
12,867 | 2015-05-06 | 0 |
WEINER DAVID M. CHIEF MEDICAL OFFICER |
|
5,028 | 2015-05-06 | 0 |
ANDREWS RONALD ASBURY PRESIDENT, MEDICAL SCIENCES |
|
3,330 | 2012-04-27 | 0 |
STEVENSON MARK PRESIDENT & COO |
|
49,699 | 2011-08-22 | 0 |
|
1,133 | 2011-08-22 | 0 | |
LUCIER GREGORY T CHIEF EXECUTIVE OFFICER |
|
335,878 | 2011-08-05 | 0 |
|
70,000 | 2011-08-01 | 0 | |
|
13,000 | 2009-05-11 | 0 | |
|
2,747 | 2009-05-08 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-05-26 16:30:16 -0400 | 2022-05-24 | A | 516,280 | a | 516,280 | direct | ||||||||||
2022-05-26 16:32:49 -0400 | 2022-05-24 | A | 75,347 | a | 75,347 | direct | ||||||||||
2022-05-26 16:34:50 -0400 | 2022-05-24 | A | 88,097 | a | 88,097 | direct | ||||||||||
2022-04-28 19:39:09 -0400 | 2022-04-26 | A | 6,000 | a | 6,000 | direct | ||||||||||
2022-04-28 19:42:58 -0400 | 2022-04-26 | A | 6,000 | a | 6,000 | direct | ||||||||||
2022-04-28 19:46:57 -0400 | 2022-04-26 | A | 6,000 | a | 6,000 | direct | ||||||||||
2022-04-28 19:50:16 -0400 | 2022-04-26 | A | 6,000 | a | 6,000 | direct | ||||||||||
2022-04-28 19:53:12 -0400 | 2022-04-26 | A | 6,000 | a | 6,000 | direct | ||||||||||
2022-04-28 19:57:39 -0400 | 2022-04-26 | A | 6,000 | a | 6,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ATYR PHARMA INC LIFE | 2022-06-24 22:15:03 UTC | 0.7512 | 0.8188 | 1100000 |
ATYR PHARMA INC LIFE | 2022-06-24 21:45:03 UTC | 0.7512 | 0.8188 | 1100000 |
ATYR PHARMA INC LIFE | 2022-06-24 21:15:04 UTC | 0.7512 | 0.8188 | 1100000 |
ATYR PHARMA INC LIFE | 2022-06-24 20:45:03 UTC | 0.7512 | 0.8188 | 1100000 |
ATYR PHARMA INC LIFE | 2022-06-24 20:15:03 UTC | 0.7512 | 0.8188 | 1100000 |
ATYR PHARMA INC LIFE | 2022-06-24 19:45:03 UTC | 0.7512 | 0.8188 | 1100000 |
ATYR PHARMA INC LIFE | 2022-06-24 19:15:03 UTC | 0.7512 | 0.8188 | 1100000 |
ATYR PHARMA INC LIFE | 2022-06-24 18:45:03 UTC | 0.7512 | 0.8188 | 1100000 |
ATYR PHARMA INC LIFE | 2022-06-24 18:15:04 UTC | 0.7512 | 0.8188 | 1100000 |
ATYR PHARMA INC LIFE | 2022-06-24 17:45:03 UTC | 0.7512 | 0.8188 | 1100000 |
ATYR PHARMA INC LIFE | 2022-06-24 17:15:03 UTC | 0.7512 | 0.8188 | 1100000 |
ATYR PHARMA INC LIFE | 2022-06-24 16:45:03 UTC | 0.7656 | 0.8044 | 1100000 |
ATYR PHARMA INC LIFE | 2022-06-24 16:15:03 UTC | 0.7656 | 0.8044 | 1100000 |
ATYR PHARMA INC LIFE | 2022-06-24 15:45:03 UTC | 0.7656 | 0.8044 | 450000 |
ATYR PHARMA INC LIFE | 2022-06-24 15:15:03 UTC | 0.7656 | 0.8044 | 450000 |
ATYR PHARMA INC LIFE | 2022-06-24 14:45:03 UTC | 0.7734 | 0.7966 | 450000 |
ATYR PHARMA INC LIFE | 2022-06-24 14:15:03 UTC | 0.7734 | 0.7966 | 450000 |
ATYR PHARMA INC LIFE | 2022-06-24 13:45:03 UTC | 0.7734 | 0.7966 | 450000 |
ATYR PHARMA INC LIFE | 2022-06-24 13:15:03 UTC | 0.7734 | 0.7966 | 450000 |
ATYR PHARMA INC LIFE | 2022-06-24 12:45:03 UTC | 0.7734 | 0.7966 | 450000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund | LIFE | -16795.0 shares, $-95563.55 | 2022-01-31 | N-PORT |
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund | LIFE | -2864.0 shares, $-15322.4 | 2022-03-31 | N-PORT |